— Team of seasoned scientific advisors to further guide InfanDx on diagnostic needs and product concepts in neonatal acute and critical care
— Inaugurating meeting focused on positioning of HypoxE® Test in HIE management, US market entry strategy, and further product pipeline
InfanDx AG (Cologne, Germany), a privately-held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for acute and critical care of newborns, today announced the establishment of its newly formed international Scientific Advisory Board. This will provide InfanDx with access to unparalleled scientific and clinical expertise in neonatal diagnostics, metabolomics, and biostatistics. Read more…
Eisbach Bio and MD Anderson Announce Strategic Collaboration to Develop Medicines Targeting Epigenetic Machinery in Oncology
Eisbach Bio GmbH and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson’s Therapeutics Discovery division with the innovative discovery platform and allosteric assay technology of Eisbach to generate medicines that selectively disrupt genome replication and DNA repair in cancers harboring defined genetic alterations.
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.
“I am pleased to welcome Ron to the senior leadership team at T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Ron is a seasoned executive who has led the legal, compliance and business operations functions at several innovative biotech companies, and additionally has specialized expertise in patent law. As a rapidly growing organization with multiple pipeline programs, his contributions will be instrumental as we pursue our mission of developing best-in-class T-cell receptor (TCR) therapies to transform patient outcomes.”